SnowWorld N.V. — M&A Activity 2007

Sep 11, 2007

PRESS RELEASE

Lelystad, 11 September 2007

Fornix BioSciences N.V. ("Fornix") is currently in discussions with Mosadex C.V. ("Mosadex") regarding the possible sale of its division Dr. Fisher Farma B.V. In relation thereto parties have signed a letter of intent on 6 September 2007. The Supervisory Board of Fornix has given its approval during the evening of Monday September 10th for Fornix to continue to explore this possible sale to Mosadex on the basis of the aforementioned letter of intent. Fornix expects to be able to provide further information on the possible sale before the end of September.

Dr. Fisher Farma specialises in purchasing, import, marketing, export, sale and distribution of a wide range of patented drugs to pharmacists and pharmaceutical wholesalers in the European Union. With a turnover of euro 29.7 million the share of Dr. Fisher Farma in the total turnover of Fornix was over 60% (2006H01: euro 30.3 million, representing 64%, financial year 2006: Turnover Dr. Fisher Farma euro 61.2 million, representing 63%). The contribution of Dr. Fisher Farma to the EBIT of Fornix amounts to 3% over the first half year of 2007 (2006H01: 6%; financial year 2006: 5%).

Mosadex is a Dutch wholesaler with two full product range distribution centres. Based on sales and size Mosadex is the third largest pharmaceutical wholesaler in the Netherlands.

Fornix BioSciences N.V. C.L. Bergman Chairman of the Executive Board Tel. (0320) 26 77 99

http://www.fornix.nl

END OF PRESS RELEASE

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which focuses on the development and sale of diagnostic and therapeutic allergen products, the distribution of medical aids and medical and nursing consumables and the distribution of patented drugs within the EU. Fornix BioSciences has facilities in Lelystad and Beuningen in the Netherlands and Hamburg in Germany. The company employs 200 people and has large customer base in the Netherlands and thirteen other European countries.

The activities are carried on by three divisions, which in turn are made up of operating companies.

The Allergy Division, the most profitable division, consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland. It specialises in the development, production and sale of a broad range of patient-friendly immunotherapeutic products under several brand names, including Oralgen® and Igevac® , used to treat allergies caused by agents such as grass and tree pollen and house-dust mites. The development of these products is supported by high-quality R&D and pan-European clinical studies of effectivity.

The Medical Aids Division, consisting of Laprolan/ComforMed in Beuningen, specialises in the marketing, sale and distribution of an extensive range of medical aids and medical and nursing consumables.

The Trading Division, consisting of Dr. Fisher Farma, specialises in purchasing, import, marketing, export, sale and distribution of a wide range of patented drugs to pharmacists and pharmaceutical wholesalers in the Netherlands and thirteen other EU countries.